Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20603229 | 0.81 | MEN1 (0.39) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL681238 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL28616760 | 0.79 | FDPS (0.39) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL176118 | 0.76 | ALDH1A1 (0.32) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL1728131 | 0.75 | ALDH1A1 (0.45) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL3258261 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL3176588 | 0.73 | ALOX15 (0.46) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Hydroxyl Radical SCHEMBL868217 | 0.73 | MEN1 (0.40) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL4653162 | 0.73 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL1417855 | 0.73 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240410274-A1 | METHODS AND MATERIALS FOR MONITORING STIMULATION EFFECTIVENESS | CHEVRON U.S.A. INC. | 2024-12-12 | — | — | US | claimed |
| EP-3566693-B1 | EYE DEVICE | EYED PHARMA (BE) | 2021-02-17 | — | — | EP | claimed |
| EP-3566693-A1 | EYE DEVICE | EyeD Pharma (BE) | 2019-11-13 | — | — | EP | claimed |
| EP-3068372-B1 | EYE DEVICE | EYED PHARMA (BE) | 2019-05-08 | — | — | EP | claimed |
| US-9999595-B2 | Eye device | EYED PHARMA (BE) | 2018-06-19 | — | — | US | claimed |
| US-20160287513-A1 | EYE DEVICE | EYED PHARMA (BE) | 2016-10-06 | — | — | US | claimed |
| EP-3068372-A1 | EYE DEVICE | EyeD Pharma (BE) | 2016-09-21 | — | — | EP | claimed |
| WO-2015071427-A1 | EYE DEVICE | EYED PHARMA (BE) | 2015-05-21 | — | — | WO | claimed |
| US-20100080830-A1 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | PSIVIDA INC. (US) | 2010-04-01 | — | — | US | claimed |
| US-20060099256-A1 | Microspheres and related processes and pharmaceutical compositions | PRICE JAMES C | 2006-05-11 | — | — | US | claimed |
| WO-2004050066-A1 | MICROSPHERES AND RELATED PROCESSES AND PHARMACEUTICAL COMPOSITIONS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040115268-A1 | Systemic delivery of antiviral agents | CONTROL DELIVERY SYSTEMS, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004043435-A2 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | CONTROL DELIVERY SYSTEMS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| CN-115697363-B | Composition for activating cell-killing T Cells (CTL) | DIC CORP. (JP) | 2026-05-26 | — | — | CN | disclosed |
| US-20240115634-A1 | COMPOSITION FOR SUPPRESSING DETERIORATION OF OR ENHANCING MEMORY LEARNING FUNCTION AND/OR COGNITIVE FUNCTION | DIC CORPORATION (JP) | 2024-04-11 | — | — | US | disclosed |
| CN-117794392-A | Composition for preventing or improving motor organ syndrome | DIC株式会社 | 2024-03-29 | — | — | CN | disclosed |
| US-4732760-A | ANTISECRETORY AGENTS | THE GREEN CROSS CORPORATION (JP) | 1988-03-22 | — | — | US | disclosed |
| EP-0142036-A1 | Pharmaceutical agent for ulcers of the gastro-intestinal tract | GREEN CROSS CORPORATION (JP) | 1985-05-22 | — | — | EP | disclosed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3961628-A | Ocular drug dispensing system | ALZA CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080830-A1 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | HAVCR2, MAVS, PGF | ALDH1A1 915/4885TSHR 2720/4885MEN1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.